Data Year:

For its 2025 fiscal year, IOVANCE BIOTHERAPEUTICS, INC., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Frederick G. Vogt Ph.D., J.D.
Interim Chief Executive Officer and President, General Counsel
Total Compensation $1,888,175 View details Pay Rank By Title In Biotechnology industry #30 View more
Jean-Marc Bellemin
Former Chief Financial Officer
Total Compensation $663,104 View details Pay Rank By Title In Biotechnology industry #482 View more
Igor Bilinsky Ph.D.
Chief Operating Officer
Total Compensation $1,118,062 View details Pay Rank By Title In Biotechnology industry #136 View more
Raj K. Puri M.D., Ph.D.
Chief Regulatory Officer
Total Compensation $1,341,778 View details Pay Rank By Title In Biotechnology industry #235 View more
Corleen Roche
Chief Financial Officer
Total Compensation $1,455,980 View details Pay Rank By Title In Biotechnology industry #302 View more
Matthew W. Rosinack
Interim Principal Financial Officer and Principal Accounting Officer
Total Compensation $782,491 View details Pay Rank By Title In Biotechnology industry #442 View more
Daniel Kirby
Chief Commercial Officer
Total Compensation $2,160,594 View details Pay Rank By Title In Biotechnology industry #148 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at IOVANCE BIOTHERAPEUTICS, INC. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. IOVANCE BIOTHERAPEUTICS, INC. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. IOVANCE BIOTHERAPEUTICS, INC. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Frederick G. Vogt Ph.D., J.D.
Interim Chief Executive Officer and President, General Counsel
Total Cash $1,112,000 Equity $759,375 Other $16,800 $1,888,175
Jean-Marc Bellemin
Former Chief Financial Officer
Total Cash $277,454 Equity $379,688 Other $5,962 $663,104
Igor Bilinsky Ph.D.
Chief Operating Officer
Total Cash $724,574 Equity $379,688 Other $13,800 $1,118,062
Raj K. Puri M.D., Ph.D.
Chief Regulatory Officer
Total Cash $853,358 Equity $474,620 Other $13,800 $1,341,778
Corleen Roche
Chief Financial Officer
Total Cash $487,688 Equity $961,830 Other $6,462 $1,455,980
Matthew W. Rosinack
Interim Principal Financial Officer and Principal Accounting Officer
Total Cash $543,298 Equity $239,193 Other $0 $782,491
Daniel Kirby
Chief Commercial Officer
Total Cash $792,214 Equity $1,356,563 Other $11,817 $2,160,594
For its 2024 fiscal year, IOVANCE BIOTHERAPEUTICS, INC., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Athena Countouriotis, M.D. Total Cash $1,329,492
Iain Dukes, D.Phil. Total Cash $2,618,992
Merrill A. McPeak Total Cash $872,056
Michael Weiser, M.D., Ph.D. Total Cash $2,423,992
Ryan Maynard Total Cash $1,329,492
Wayne Rothbaum Total Cash $1,919,000
Wendy Yarno Total Cash $902,242
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.